Raymond James & Associates Rhythm Pharmaceuticals, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
Shares
1 transactions
Others Institutions Holding RYTM
# of Institutions
189Shares Held
67.1MCall Options Held
834KPut Options Held
78.6K-
Primecap Management CO Pasadena, CA7.22MShares$412 Million0.28% of portfolio
-
Black Rock Inc. New York, NY6.74MShares$385 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY6.4MShares$366 Million3.59% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.08MShares$348 Million4.44% of portfolio
-
Goldman Sachs Group Inc New York, NY3.88MShares$222 Million0.03% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $3.18B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...